Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States
European Journal of Neurology · 2025-09 · 32 (9)
DOI: 10.1111/ene.70360 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 18.09.2025. Verfasst von Narghes Calcagno und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Bosto…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Phenylbutyrates. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amylyx Pharmaceuticals Inc.
Abstract (Originalsprache)
Introduction/Aims Sodium phenylbutyrate ( PB ) and taurursodiol ( TURSO )— PB and TURSO —was approved as a treatment for amyotrophic lateral sclerosis ( ALS ) in the United States in 2022 based on the results of a phase 2 trial, but was voluntarily withdrawn from the market in 2024 after negative results from its phase 3 trial. The objective of our study was to describe the real‐world clinical experience with PB and TURSO at one ALS clinic.
Methods
This was a retrospective chart review of all ALS patients receiving a PB and TURSO prescription at the Massachusetts General Hospital ALS Clinic between October 1, 2022, and September 30, 2023. Data were extracted from patients' electronical medical records up to December 31, 2023.
Results
A total of 441 ALS patients received a PB and TURSO prescription, with 329 (75%) initiating the medication. The average length of treatment was 285 days, and the rate of drug discontinuation during the study period was 41% (N=135). The most common reason for drug discontinuation was side effects (N=93, 69%), with the most common being gastrointestinal issues (N=69). No hospitalizations, deaths, or serious adverse events were considered related to treatment with PB and TURSO.
Discussion
Experience in real‐world clinical settings can help supplement trial data with information on the drug performance at various stages of disease progression. Adverse events impacted treatment persistence in routine clinical practice, underscoring the need for vigilant monitoring and tailored supportive interventions to optimize treatment adherence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.
- Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
- Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Narghes Calcagno, Erica Scirocco, Dylan V Neel, deMauri S Mackie, James D Berry, Sabrina Paganoni
Förderung
- Amylyx Pharmaceuticals Inc
Zitieren
APA
Calcagno, N., Scirocco, E., Clampffer, E., Addy, G., Morgan, S., Parikh, N., Neel, D. V., Scalia, J., Young, R., Locatelli, M., Mackie, D. S., Berry, J. D., & Paganoni, S. (2025). Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States. European Journal of Neurology, 32(9). https://doi.org/10.1111/ene.70360
Vancouver
Calcagno N, Scirocco E, Clampffer E, Addy G, Morgan S, Parikh N, et al. Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States. European Journal of Neurology. 2025;32(9). doi:10.1111/ene.70360
BibTeX
@article{Calcagno2025,
author = {Calcagno, Narghes and Scirocco, Erica and Clampffer, Erin and Addy, Grace and Morgan, Sean and Parikh, Neel and Neel, Dylan V and Scalia, Jennifer and Young, Rebekah and Locatelli, Matteo and Mackie, deMauri S and Berry, James D and Paganoni, Sabrina},
title = {Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {9},
doi = {10.1111/ene.70360}
}
EUVIMED